Preferred salvage regimens for Ibrutinib and Idelalisib-Rituximab

Preferred salvage regimens for Ibrutinib and Idelalisib-Rituximab

ScrippsHealth

4 years
278 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Susan M. O'Brien, MD of University of California Irvine the preferred salvage regimens for Ibrutinib and Idelalisib-Rituximab at Scripps Health 36th Annual Conference: Clinical Hematology and Oncology in San Diego. www.scrippshealth.org/cancer
Up Next Autoplay